Provided by Tiger Fintech (Singapore) Pte. Ltd.

Myriad Genetics

10.01
+0.10001.01%
Post-market: 10.010.00000.00%17:39 EDT
Volume:1.91M
Turnover:19.10M
Market Cap:914.00M
PE:-7.10
High:10.30
Open:9.79
Low:9.68
Close:9.91
Loading ...

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?

StockStory
·
17 Mar

Myriad Genetics Inc : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $12.5 From $11.5

THOMSON REUTERS
·
12 Mar

Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley

TIPRANKS
·
12 Mar

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

StockStory
·
11 Mar

US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results

Simply Wall St.
·
05 Mar

Myriad Genetics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
05 Mar

Piper Sandler Keeps Their Hold Rating on Myriad Genetics (MYGN)

TIPRANKS
·
04 Mar

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

StockStory
·
04 Mar

Myriad Genetics Is Maintained at Underperform by B of A Securities

Dow Jones
·
03 Mar

Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes

TIPRANKS
·
02 Mar

BRIEF-Myriad Genetics And Gabbi To Work Together To Increase Access To Hereditary Cancer Risk Assessment Tools

Reuters
·
28 Feb

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

THOMSON REUTERS
·
28 Feb

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

GlobeNewswire
·
28 Feb

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Simply Wall St.
·
27 Feb

Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
26 Feb

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

Benzinga
·
26 Feb